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Abstract
Background: Endothelin(ET) axis plays a key role in many tumor progression and metastasis via
various mechanisms such as angiogenesis, mediating extracellular matrix degradation and inhibition
of apoptosis. However, there is limited information regarding the clinical significance of plasma big
ET-1 levels in esophageal cancer patients. Circulating plasma big ET-1 levels were measured in
patients with esophageal squamous cell carcinoma(ESCC) to evaluate the value of ET-1 as a
biomarker for predicting tumor recurrence and patients survival.
Methods: Preoperative plasma big ET-1 concentrations were measured by an enzyme linked
immunosorbent assay(ELISA) in 108 ESCC patients before surgery, and then again at 1,2,3,10 and
30 days after curative radical resection for ESCC. The association between preoperative plasma big
ET-1 levels and clinicopathological features, tumor recurrence and patient survival, and their
changes following surgery were evaluated.
Results: The preoperative plasma big ET-1 levels in ESCC patients were significantly higher than
those in controls. And there was a significant association between plasma big ET-1 levels and
disease stage, as well as invasion depth of the tumor and lymph node status. Furthermore, plasma
big ET-1 levels decreased significantly after radical resection of the primary tumor and patients with
postoperative recurrence had significantly higher plasma big ET-1 levels than that of patients
without recurrence. Finally, the survival rate of patients with higher plasma big ET-1 concentrations
(>4.3 pg/ml) was significantly lower than that of patients with lower level (≤ 4.3 pg/ml). Multivariate
regression analysis showed that plasma big ET-1 level is an independent prognostic factor for
survival in patients with ESCC.
Conclusion: Plasma big ET-1 level in ESCC patients may reflect malignancy and predict tumor
recurrence and patient survival. Therefore, the preoperative plasma big ET-1 levels may be a
clinically useful biomarker for choice of multimodality therapy in ESCC patients.
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Background
The incidence of esophageal cancer shows a striking geo-
graphic variation in the world: a 20-fold variation is
observed between high-risk China and low-risk western
Africa[1]. Recently, advances in surgical techniques and
peri-operative management significantly improved the
outcome of patients with squamous cell carcinoma of the
esophagus. However, the overall survival remains poor
and the five year survival rate remains below 30 percent in
patients with esophageal cancer after a curative
esophagectomy[2-4]. Many results[5-8] demonstrated the
prognosis in patients with esophageal cancer mainly
depends on tumor stage, but other multiple factors,
including age, gender, the size of tumor and some molec-
ular markers, will influence tumor response to therapy.
Accurate prognostic factor is essential for selecting
patients who are suitable for combined-modality therapy.
The use of circulating prognostic biomarkers is a conven-
ient way to achieve the objective[9].
Endothelins(ETs), including ET-1, ET-2 and ET-3, are
small 21-residue peptides[10]. There are at least two
receptor subtypes, endothelin A receptors(ETAR) and
endothelin B receptors(ETBR), belonging to the family of
G-protein-linked receptors with seven transmembrane-
spanning domains[11]. The ET-1 gene encodes a precur-
sor peptide, preproendothelin-1, which is cleaved by a
neutral endopeptidase to form proendothelin-1 or big ET-
1. Due to a low circulating concentration and a short
plasma half-life (about 1.5 min), measurement of plasma
ET-1 concentrations has proven to be difficulty. Big ET-1
is a stable peptide with a plasma half-life of 30 minutes,
making the measurement of plasma big ET-1 concentra-
tions a sensitive indicator of endothelin system activa-
tion[12,13]. Recent studies [14-18] have suggested that
ET-1 may play an important role in tumorigenesis, tumor
progression and metastasis presumably by various mech-
anisms, including mitogenesis, inhibition of apoptosis,
angiogenesis and mediating extracellular matrix degrada-
tion.
According to our previous study[19], ET-1 can increase the
invasive ability of human esophageal cancer cells. How-
ever, it is unclear about prognostic significance of preop-
erative plasma big ET-1 in patients with ESCC. In this
study, we evaluated: 1)plasma big ET-1 levels in ESCC
patients and in healthy controls, 2) its correlation with
clinicopathologic features, tumor recurrence and patient
survival, and 3) the effect of surgery on plasma big ET-1
levels.
Methods
Patient Selection
The study population consists of 122 consecutive patients
who underwent radical resection at our hospital between
March of 2000 and August of 2002. All patients had been
confirmed as esophageal squamous cell carcinoma by
postoperative histopathologic assessment. Tumor stage
was classified by the routine histopathologic assessment
according to the UICC TNM staging system [20]. Patients
who had received chemotherapy and/or radiotherapy
before surgery were excluded from the study. Patients with
co-morbid conditions that are associated with elevated
ET-1, such as hypertension, cardiac failure, myocardial
infarction and rheumatic diseases, were excluded. Moreo-
ver, 122 patients were asked about their habits of smoking
and drinking. They were divided into three groups strati-
fied by the number of cigarettes per day(cps) defined as
non-smoker(have not smoked yet or very rarely tried to
smoke), light-smoker(less than 20 cps) and heavy-
smoker(more than 20 cps). And the patients were also
divided into three groups stratified by ethanol intake lev-
els defined as non-drinker (less than 1 g/day), light-
drinker (1–50 g/day) and heavy-drinker (more than 50 g/
day). Fourteen patients which were heavy smokers and/or
drinkers were excluded in order to avoid potential inter-
ference. Out of a total of 122 such patients, 108 patients
were the subjects of the present study. There were 78 men
and 30 women with a median age of 64.5(range, 44–79)
years.
The control group consisted of 82 age- and sex-matched
healthy individuals(median age 65.3 [range, 40–72]
years; 44 men and 38 women) without any evidence of
disease. Moreover, we also collected data in 26 light-
smokers, 35 heavy-smokers, 32 light-drinkers and 38
heavy-drinkers without ESCC and/or co-morbid condi-
tions. The regional ethics committee approved the project.
Patients were followed and the date and cause of death
was recorded. The diagnosis of local/regional recurrence
and distant metastases were confirmed by histology and/
or imaging findings.
Blood collection and assays
Peripheral venous blood samples were drawn into sterile
glass tubes in the morning between 7 and 8 hours after an
overnight fast. All blood samples was collected in EDTA
specimen tubes, placed immediately into an ice bag and
centrifuged at 2,000 rpm for 10 minutes at 4°C within 15
minutes of blood collection. Plasma was separated, aliq-
uoted, and stored at -70°C until assay. Plasma samples
were collected and stored on admission and 1,2,3,10 and
30 days following surgery. Plasma big ET-1 concentrations
were measured using a one-step sandwich enzyme immu-
noassay kit (Biomedica, Vienna, Austria) in accordance
with the manufacturer's protocol. The kit consisted of
purified polyclonal antibody and monoclonal detection
antibody highly specific for big ET-1. Big ET-1 binds to the
pre-coated antibody and forms a sandwich with the detec-
tion antibody. Plasma big ET-1 concentrations were calcu-BMC Cancer 2008, 8:334 http://www.biomedcentral.com/1471-2407/8/334
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lated by extrapolation from a standard curve. A separate
standard curve was constructed for each ELISA batch. All
standards and patient samples were analyzed in duplicate
and the mean value was taken.
Statistical analysis
The values of the plasma big ET-1 was written as mean ±
standard deviation. T test and ANOVA were used to eval-
uate differences between multiple groups, unpaired and
paired observations, respectively. Kaplan-Meier survival
curves and the log rank test were used to analyses survival
differences. Univariate and multivariate analyses (Cox's
proportional hazard) of all clinicopathological variables
were performed using SPSS version 10.1 (SPSS Inc, Chi-
cago, IL, USA). A p value of less than 0.05 was considered
significant.
Results
1) Preoperative plasma big ET-1 levels
Preoperative plasma big ET-1 levels (4.70 ± 0.81 pg/mL)
in patients with ESCC were significantly higher than those
in controls (3.31 ± 0.78 pg/mL, P < 0.001), light-smok-
ers(3.44 ± 0.71, P = 0.005) and light-drinker(3.36 ± 0.83,
P = 0.003), heavy-smokers(4.12 ± 0.56, P = 0.020) and
heavy-drinkers(3.86 ± 0.75, P = 0.011). Moreover, the lev-
els in controls were significantly lower than those in
heavy-smokers(P = 0.010) and heavy-drinkers(P = 0.038)
without ESCC, and were no statistically different com-
pared to the levels of light-smoker(P = 0.250) and light-
drinker(P = 0.382).
The relationships between plasma big ET-1 levels and
clinicopathologic variables are shown in Table 1. The cor-
relation between plasma big ET-1 levels and the invasion
depth of the tumor was statistically significant by ANOVA.
Patients with tumors penetrating the muscle (T3) had sig-
nificantly higher plasma big ET-1 levels when compared
to those with tumors limited to the mucosa, submucosa
or muscle(T1/2). And patients with lymph node metasta-
sis had significantly higher big ET-1 levels when compared
with those without metastatic disease. Moreover, there
was a significant correlation between plasma big ET-1 lev-
Table 1: Correlation between preoperative plasma big ET-1 levels and clinicopathologic variables in ESCC patients
Characteristic Number of patients (n) Preoperative plasma big ET-1 levels (pg/ml) P value
Gender
Male 78 4.62 ± 0.72 0.285
Female 30 4.85 ± 0.63
Age, y
≤ 60 yrs 41 4.67 ± 0.55 0.876
>60 yrs 67 4.72 ± 0.86
Smoking
Light-smoker 42 4.78 ± 0.39 0.386
Non-smoker 66 4.65 ± 0.64
Drinking
Light-drinker 35 4.73 ± 0.27 0.674
Non-drinker 73 4.68 ± 0.50
Site of tumor
upper 12 4.75 ± 0.91 0.763
Middle 57 4.70 ± 0.57
Lower 39 4.69 ± 0.83
Tumor differenciation
Well 30 4.61 ± 0.54 0.354
Moderate 48 4.64 ± 0.68
Poor 30 4.88 ± 0.47
Tumor class
T1 33 4.42 ± 0.61 0.001
T2 38 4.60 ± 0.34
T3 37 5.01 ± 0.84
T4 0 0
Lymph node metastasis
N0 63 4.45 ± 0.59 <0.001
N1 45 5.06 ± 0.63
Stage
I 28 4.41 ± 0.52 0.003
II 48 4.68 ± 0.76
III 32 5.25 ± 0.82
IV 0 0BMC Cancer 2008, 8:334 http://www.biomedcentral.com/1471-2407/8/334
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els and disease stage, with higher big ET-1 levels detected
as the disease stage increased.
There were no significant associations between plasma big
ET-1 levels and gender, age, tumor location and degree of
differentiation.
2) The effect of surgery on plasma big ET-1 Levels
The effect of surgical resection of the tumor was evaluated
by sequential measurement of plasma big ET-1 levels
before surgery and at 1,2,3,10 and 30 postoperative
days(POD) following surgery. Radical resection including
subtotal esophagectomy and removal of the regional
lymph nodes (two-field lymph node dissection) was per-
formed in all 108 patients. The plasma big ET-1 levels on
the first and second postoperative day increased signifi-
cantly compared with preoperative levels in 108 patients,
but decreased on the 3rd POD with no significant differ-
ence compared to the pre-operative levels. And then, there
was a subsequent decrease with the 10 day postoperative
levels being significantly lower than preoperative levels.
The plasma big ET-1 levels at 30 days remain stable when
compared with 10 days postoperative values(P =
0.273).(Figure 1)
3) The overview of follow-up
All patients lived at least 30 days after surgery, and were
followed-up using a standard protocol after discharge
from the hospital. The mean follow-up period was 34.2
months (7~60 months). Cancer-specific survival was cal-
culated from the date of operation until date of death or
last follow-up. Survival was censored for patients who
died without disease progression. During the study, 63
patients died from ESCC progression (including 19
patients who developed local/regional recurrences and 44
patients who developed distant recurrences) and 45
patients remained alive, 7 of them with documented
tumor recurrence.
4) Correlations between preoperative plasma big ET-1 
levels and patients survival
Because 4.3 pg/mL was the upper limit of plasma big ET-
1 concentrations in healthy controls(2.9~4.3 pg/mL), the
value was regarded as a threshold according to previous
report[9,12]. Elevated plasma big ET-1 levels were found
in 71(65.7%) patients. The overall survival rate of patients
with higher plasma big ET-1 concentrations (>4.3 pg/ml)
was significantly lower than that of patients with lower
level(≤ 4.3 pg/ml).(Figure 2)
Changes in plasma big ET-1 levels following esophagectomy Figure 1
Changes in plasma big ET-1 levels following esophagectomy. *elevated on POD1 and POD2(P < 0.001) and **reduced 
on POD10 and POD30(P < 0.001) compared with preoperative levels.
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Prognostic variables evaluated in a univariate analysis
included age, gender, tumor location, differentiation, T
class, lymph node status, TNM stage and preoperative
plasma big ET-1 level. (Table 2) Multivariate regression
analysis identified four variables, T class, lymph node sta-
tus, TNM stage and preoperative plasma big ET-1 concen-
tration as having independent prognostic value for overall
survival. (Table 3)
5) Correlations among preoperative plasma big ET-1 
levels, tumor recurrence and survival
Patients with recurrence had significantly higher preoper-
ative plasma big ET-1 levels than patients without recur-
rence(5.42 ± 0.66 pg/ml versus 4.46 ± 0.48 pg/ml, P =
0.002). About 78.6%(55/70) patients with tumor recur-
rence remained high plasma big ET-1 level (>4.3 pg/ml)
when tumor recurrence were found. Moreover, in the
patients with tumor local-regional and/or distant recur-
rence, the disease-free survival rate of patients with ele-
vated plasma big ET-1 concentrations (>4.3 pg/ml) was
significantly lower than that of patients with lower level(≤
4.3 pg/ml).(Figure 3)
Discussion
To date, pathologic stage is the most valuable single prog-
nostic attribute in esophageal cancer patients. In the
present study, we evaluated preoperative plasma big ET-1
levels in healthy controls and in ESCC patients using a val-
idated ELISA. Our study shows a marked difference
between preoperative plasma big ET-1 concentrations in
Kaplan-Meier survival curve in relation to preoperative plasma big ET-1 levels in patients with ESCC Figure 2
Kaplan-Meier survival curve in relation to preoperative plasma big ET-1 levels in patients with ESCC. The over-
all survival of patients with elevated big ET-1 levels was significantly lower than that of patients with normal levels(log-rank test 
P = 0.001).
7LPHPRQWKV
70 60 50 40 30 20 10 0
2
Y
H
U
D
O
O

V
X
U
Y
L
Y
D
O

1.2
1.0
.8
.6
.4
.2
3 ORJUDQNWHVW
1RUPDO ELJ(7
SJPO
(OHYDWHG ELJ(7
!SJPOBMC Cancer 2008, 8:334 http://www.biomedcentral.com/1471-2407/8/334
Page 6 of 9
(page number not for citation purposes)
ESCC patients when compared with age and sex-matched
healthy controls, with a significant association between
these levels and tumor invasion depth, lymph node status
and TNM stage. Univariate and multivariate survival anal-
ysis confirmed that pre-operative plasma big ET-1 level
were an independent predictor of survival in patients with
ESCC.
Some findings[21-24] suggest that ET-1 may act as an
autocrine or paracrine growth factor mediating through
its receptor, ETAR or ETBR. It is well established that
endothelin axis plays an important role in a series of
events relating with tumor development, including
mitogenesis[25,26] and escape from apoptosis[27,28].
Moreover, ET-1 expression has been linked to induction
of endothelial cell growth, angiogenesis[29-31] and epi-
thelial-to-mesenchymal transition[32-34] resulting in an
increased invasiveness and metastases of some tumors.
ET-1 expression in ESCC has been associated with its
prognostic significance[35]. Our findings are in agree-
ment with the observations and correlate preoperative
plasma big ET-1 levels with cancer-specific survival. Based
on our results, we identified elevated level of preoperative
plasma big ET-1 could act as a marker of aggressive disease
and poor survival in ESCC. We speculate that increased
plasma big ET-1 level may indicate more tumor load and/
or unidentified micrometastatic disease, predicting a poor
survival in patients.
In our study, the mean plasma big ET-1 levels were mark-
edly increased on the 1st and 2nd POD in ESCC patients.
The phenomenon may partly contribute to a compensa-
tory response to surgical stress, for example, the reduction
of local blood flow in nonvital organs so as to increase the
blood flow in vital organs[36]. Several prior reports[37-
39] suggest that tissue damage, ischemia and surgical
stress during operation could raise circulating ET-1 levels,
and the elevated ET-1 levels related to surgery frequently
peak between 1 and 12 hours in the immediate post-oper-
ative period and declined gradually thereafter. On the 3rd
POD, the plasma big ET-1 levels declined, but were no sta-
tistically different compared to the pre-operative levels. It
implies that the increasing levels of big ET-1 as response
to surgical stress were lessen. On the 10th and 30th POD,
these levels declined significantly compared to pre-opera-
tive levels. Ferrari-Bravo[40] and Teng[41] also reported
that postoperative plasma big ET-1 level markedly
decreased compared with preoperative concentrations in
patients with gastric carcinoma, and concluded that ET-1
may be secreted by the cancer cell and the ET-1 concentra-
tion will fall in when the tumor is removed. These find-
ings[35,40,41], along with our results, suggest that plasma
big ET-1 might be able to be used as a measure of surgical
completeness.
During the study, preoperative plasma big ET-1 levels
were an important independent prognostic factor for
postoperative tumor recurrence in patients with ESCC.
Those patients with recurrence had significantly higher
preoperative plasma big ET-1 levels than patients without
recurrence and the overall and disease-free survival rate of
patients with elevated plasma big ET-1 concentrations was
significantly lower than that of patients with normal level.
Our findings suggest that increased plasma big ET-1 level
may indicate unidentified micrometastatic disease, and
may be used for predicting tumor recurrence in a propor-
tion of patients with ESCC. Postoperative tumor recur-
rence is not uncommon even in patients undergoing a
Table 2: Univariate analysis for predictors of overall survival in patients with ESCC
Variable Hazard Ratio 95% Confidence Interval P value
Age (>60 vs. ≤ 60) 0.834 0.512–1.357 0.834
Gender (male vs. female) 1.183 0.727–1.924 0.499
Site of tumor (upper vs. middle vs. lower) 1.310 0.916–1.872 0.139
Differenciation (well vs. moderate vs. poor) 1.084 0.799–1.470 0.604
Tumor class (T1 vs. T2 vs. T3 vs. T4) 2.763 1.632–4.854 0.008
Lymph node status (No vs. N1) 2.978 1.541–3.647 0.010
Stage (I vs. II vs. III vs. IV) 3.037 1.451–4.860 <0.001
Plasma big ET-1 levels (normal vs. elevated) 2.494 1.302–3.806 0.002
Table 3: Multivariate analysis for predictors of overall survival in patients with ESCC
Variable Hazard Ratio 95% Confidence Interval P value
Tumor class 2.878 1.805–4.576 0.010
Lymph node status 2.921 1.951–3.988 0.015
Stage 3.083 1.259–5.731 0.002
Plasma big ET-1 levels 2.629 1.375–4.054 0.003BMC Cancer 2008, 8:334 http://www.biomedcentral.com/1471-2407/8/334
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curative resection for localized resectable esophageal can-
cer. Micrometastatic tumor cells to either lymph nodes or
distant organs which cannot be detected by preoperative
imaging techniques may be attributed to such tumor dis-
tant failure. It is logical to expect a decline in tumor recur-
rence with the use of multiple therapy in part of high-risk
patients with ESCC. To sterilize occult micrometastases in
the distant organs, adjuvant chemotherapy either alone or
in combination with radiotherapy is now commonly per-
formed in patients with esophageal cancer either before or
after an esophagectomy in an attempt to improve both
disease-relapse control and long-term survival[42].
Kaplan-Meier survival curve in relation to preoperative plasma big ET-1 levels in patients with ESCC Figure 3
Kaplan-Meier survival curve in relation to preoperative plasma big ET-1 levels in patients with ESCC. The dis-
ease-free survival of patients with elevated big ET-1 levels was significantly lower than that of patients with normal levels(log-
rank test P < 0.001).
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Conclusion
In conclusion, this study has demonstrated elevated
plasma big ET-1 levels in ESCC patients when compared
with normal controls. Preoperative plasma big ET-1 con-
centration decreases significantly following radical resec-
tion of the primary tumor and is an independent
prognostic factor for patient survival. Preoperative plasma
big ET-1 concentration can be used for predicting tumor
recurrence and may be a clinically useful biomarker for
choice of multimodality therapy in ESCC patients.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JW carried out the design of the study, the ELISA studies,
follow-up and drafted the manuscript. XJ and ZJ partici-
pated in the design of the study and performed the statis-
tical analysis. SY, LL and LJ participated in its design and
coordination. All authors read and approved the final
manuscript.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics,
2002.  CA Cancer J Clin 2005, 55:74-108.
2. Portale G, Hagen JA, Peters JH, Chan LS, DeMeester SR, Gandami-
hardja TA, DeMeester TR: Modern 5-year survival of resectable
esophageal adenocarcinoma: single institution experience
with 263 patients.  J Am Coll Surg 2006, 202:588-596.
3. Enzinger PC, Mayer RJ: Esophageal cancer.  N Engl J Med 2003,
349:2241-2252.
4. Shiozaki H, Doki Y, Kawanishi K, Shamma A, Yano M, Inoue M,
Monden M: Clinical application of malignancy potential grad-
ing as a prognostic factor of human esophageal cancers.  Sur-
gery 2000, 127:552-561.
5. Korst RJ, Kansler AL, Port JL, Lee PC, Kerem Y, Altorki NK: Down-
staging of T or N predicts long-term survival after preoper-
ative chemotherapy and radical resection for esophageal
carcinoma.  Ann Thorac Surg 2006, 82:480-484.
6. Tajima T, Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuch-
iya K, Nakasaki H, Makuuchi H: Predicting recurrence and
metastasis of primary esophageal cancer with or without
lymph node metastasis.  Oncol Rep 2006, 15:809-814.
7. Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P,
Niendorf A, Knoefel WT, Izbicki JR: Esophageal cancer: the
mode of lymphatic tumor cell spread and its prognostic sig-
nificance.  J Clin Oncol 2001, 19:1970-1975.
8. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollsch-
weiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP, Hoelscher AH:
Histomorphologic tumor regression and lymph node metas-
tases determine prognosis following neoadjuvant radioche-
motherapy for esophageal cancer: implications for response
classification.  Ann Surg 2005, 242:684-92.
9. Mai HQ, Zeng ZY, Zhang CQ, Feng KT, Guo X, Mo HY, Deng MQ,
Min HQ, Hong MH: Elevated Plasma Big ET-1 Is Associated
with Distant Failure in Patients with Advanced-Stage
Nasopharyngeal Carcinoma.  Cancer 2006, 106:1548-1553.
10. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K,
Masaki T: The human endothelin family: three structurally
and pharmacologically distinct isopeptides predicted by
three separate genes.  Proc Natl Acad Sci USA 1989, 86:2863-2867.
11. Ahmed SI, Thompson J, Coulson JM, Woll PJ: Studies on the
expression of endothelin, its receptor subtypes, and convert-
ing enzymes in lung cancer and in human bronchial epithe-
lium.  Am J Respir Cell Mol Biol 2000, 22:422-431.
12. Everson NW, Elahi MM: Prognosis of Colorectal Cancer
Patients with Elevated Endothelin-1 Concentrations.  Asian J
Surg 2004, 27:4-9.
13. Hemsen A, Ahlborg G, Ottosson-Seeberger A, Lundberg JM: Metab-
olism of big endothelin-1 (1–38) and (22–38) in the human
circulation in relation to production of endothelin-1 (1–21).
RegulPept 1995, 55:M287-297.
14. Wulfing P, Kersting C, Tio J, Fischer RJ, Wulfing C, Poremba C, Diallo
R, Bocker W, Kiesel L: Endothelin-1-, Endothelin-A-, and
Endothelin-B-Receptor Expression Is Correlated with Vas-
cular Endothelial Growth Factor Expression and Angiogen-
esis in Breast Cancer.  Clin Cancer Res 2004, 10:2393-2400.
15. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A: Endothelin-
1 induces vascular endothelial growth factor by increasing
hypoxia-inducible factor 1α in ovarian cancer cells.  J Biol Chem
2002, 277:27850-27855.
16. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi
R, Bagnato A: Endothelin-1 induces an angiogenic phenotype
in cultured endothelial cells and stimulates neovasculariza-
tion in vivo.  Am J Pathol 2000, 157:1703-1711.
17. Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosano L,
Triciuoglio D, Spinella F, Bagnato A: Endothelin-1 protects ovar-
ian carcinoma cells against paclitaxel-induced apoptosis:
requirement for Akt activation.  Mol Pharmacol 2002,
61:524-532.
18. Rosano L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, Bag-
nato A: Endothelin-1 induces tumor proteinase activation and
invasiveness of ovarian carcinoma cells.  Cancer Res 2001,
61:8340-8346.
19. Jiao WJ, Xu J, Pan H, Wang TY, Shen Y: Effect of endothelin-1 in
esophageal squamous cell carcinoma invasion and its corre-
lation with cathepsin B.  World J Gastroenterol 2007, 13:4002-4005.
20. Sobin LH, Wittekind C: TNM Classification of Malignant
Tumours.  5th edition. New York, Wiley-Liss . 
21. Boldrini L, Gisfredi S, Ursino S, Faviana P, Lucchi M, Melfi F, Mussi A,
Basolo F, Fontanini G: Expression of endothelin-1 is related to
poor prognosis in non-small cell lung carcinoma.  Eur J Cancer
2005, 41:2828-2835.
22. Donckier JE, Michel L, Van Beneden R, Delos M, Havaux X:
Increased expression of endothelin-1 and its mitogenic
receptor ETA in human papillary thyroid carcinoma.  Clin
Endocrinol (Oxf) 2003, 59:354-360.
23. Venuti A, Salani D, Manni V, Poggiali F, Bagnato A: Expression of
endothelin 1 and endothelin A receptor in HPV-associated
cervical carcinoma: new potential targets for anticancer
therapy.  FASEB J 2000, 14:2277-2283.
24. Wulfing P, Tio J, Kersting C, Sonntag B, Buerger H, Wulfing C, Euler
U, Boecker W, Tulusan AH, Kiesel L: Expression of endothelin-A-
receptor predicts unfavourable response to neoadjuvant
chemotherapy in locally advanced breast cancer.  Br J Cancer
2004, 91:434-440.
25. Kawanabe Y, Hashimoto N, Masaki T: Effects of extracellular
Ca2+ influx on endothelin-1-induced intracellular mitogenic
cascades in C6 glioma cells.  Eur J Pharmacol 2002, 435:119-123.
26. Kawanabe Y, Hashimoto N, Masaki T: B103 neuroblastoma cells
predominantly express endothelin ET(B) receptor; effects of
extracellular Ca(2+) influx on endothelin-1-induced
mitogenesis.  Eur J Pharmacol 2001, 425:173-179.
27. Nelson JB, Udan MS, Guruli G, Pflug BR: Endothelin-1 inhibits
apoptosis in prostate cancer.  Neoplasia 2005, 7:631-637.
28. Duan J, Dai S, Fang CX, Sun R, Shavali S, Sharma SK, Ebadi M, Ren J:
Phytoestrogen alpha-zearalanol antagonizes homocysteine-
induced imbalance of nitric oxide/endothelin-1 and apoptosis
in human umbilical vein endothelial cells.  Cell Biochem Biophys
2006, 45:137-145.
29. Bhargava S, Stummeyer T, Hotz B, Hines OJ, Reber HA, Buhr HJ,
Hotz HG: Selective inhibition of endothelin receptor A as an
anti-angiogenic and anti-proliferative strategy for human
pancreatic cancer.  J Gastrointest Surg 2005, 9:703-709.
30. Medinger M, Adler CP, Schmidt-Gersbach C, Soltau J, Droll A, Unger
C, Drevs J: Angiogenesis and the ET-1/ETA receptor system:
immunohistochemical expression analysis in bone metas-
tases from patients with different primary tumors.  Angiogen-
esis 2003, 6:225-231.
31. Knowles J, Loizidou M, Taylor I: Endothelin-1 and angiogenesis in
cancer.  Curr Vasc Pharmacol 2005, 3:309-314.
32. Felx M, Guyot MC, Isler M, Turcotte RE, Doyon J, Khatib AM, Leclerc
S, Moreau A, Moldovan F: Endothelin-1 (ET-1) promotes MMP-
2 and MMP-9 induction involving the transcription factorPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:334 http://www.biomedcentral.com/1471-2407/8/334
Page 9 of 9
(page number not for citation purposes)
NF-kappaB in human osteosarcoma.  Clin Sci(Lond) 2006,
110:645-654.
33. Rosano L, Spinella F, Di Castro V, NIcotra MR, Dedhar S, de Herreros
AG, Natali PG, Bagnato A: Endothelin-1 promotes epithelial-to-
mesenchymal transition in human ovarian cancer cells.  Can-
cer Res 2005, 65:11649-11657.
34. Hagemann T, Binder C, Binder L, Pukrop T, Trumper L, Grimshaw MJ:
Expression of endothelins and their receptors promotes an
invasive phenotype of breast tumor cells but is insufficient to
induce invasion in benign cells.  DNA Cell Biol 2005, 24:766-776.
35. Ishibashi Y, Hanyu N, Nakada K, Suzuki Y, Yamamoto T, Takahashi T,
Kawasaki N, Kawakami M, Matsushima M, Urashima M: Endothelin
protein expression as a significant prognostic factor in
oesophageal squamous cell carcinoma.  Eur J Cancer 2003,
39:1409-1415.
36. Onizuka M, Miyauchi T, Mitsui K, Suzuki N, Masaki T, Goto K, Hori
M:  Endothelin-1 mediates regional blood flow during and
after pulmonary operations.  J Thorac Cardiovasc Surg 1992,
104:1696-1701.
37. Battistini B, D'Orleans-Juste P, Sirois P: Endothelins: circulating
plasma levels and presence in other biologic fluids.  Lab Invest
1993, 68:600-628.
38. Shirakami G, Magaribuchi T, shingu K, Saito Y, O'higashi T, Nakao K,
Mori K: Effects of anesthesia and surgery on plasma endothe-
lin levels.  Anesth Analg 1995, 80:449-453.
39. Itoh K, Goseki N, Endo M, Hirata Y, Marumo F: Intraoperative
hemorrhage affects endothelin-1 concentrations.  Am J Gastro-
enterol 1991, 86:118-119.
40. Ferrari-Bravo A, Franciosi C, Lissoni P, Fumagalli L, Uggeri F: Effects
of oncological surgery on endothelin-1 secretion in patients
with operable gastric cancer.  Int J Biol Markers 2000, 15:56-57.
41. Teng XJ, Shen ZX, Xiang JJ, Shen L, Yuan L, Guo J, Wang XL: Pre-
and post-operative plasma big endothelin-1 levels in patients
with gastric carcinoma undergoing radical gastrectomy.  Anti-
cancer Res 2006, 26:2503-2507.
42. Nishimaki T, Shimoji H, Sunagawa H: Recent Changes and the
Future Roles of Esophageal Cancer Surgery.  Ann Thorac Cardi-
ovasc Surg 2004, 10:324-332.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/334/pre
pub